What Is CAR-T Therapy? How Is It Different from Chemotherapy?

Full summary: CAR-T cell therapy is a form of cellular immunotherapy in which a patient's own T cells are genetically engineered to recognize and attack tumor cells. Dr. Yuelin HE of GoBroad Chunfu Institute of Hematology & Oncology explains that CAR-T and chemotherapy are not substitutes for one another; they may be used at different stages or in combination depending on the disease and treatment goals. Some patients can achieve complete remission after CAR-T therapy, but it is not appropriate for everyone. Treatment decisions should be individualized based on factors such as pathological subtype, stage, molecular features, treatment history, and response to previous therapy.

If you are living with a hematologic malignancy, another type of cancer, or an autoimmune disease, you may reach a point where familiar options such as chemotherapy, radiation therapy, or targeted therapy have already been tried but have not provided the results you hoped for. At that point, it is understandable to wonder what other options may be available.

In recent years, CAR-T cell therapy has reshaped parts of the treatment landscape for blood cancers, other cancers, and some autoimmune diseases, offering a new option for selected patients.

GoBroad Chunfu Institute of Hematology & Oncology has created a CAR-T Knowledge Hub to help patients and families understand this treatment step by step. Today's topic: What is CAR-T, and how is it different from chemotherapy?

1. What Is CAR-T?

CAR-T therapy is a form of cellular immunotherapy and a newer approach to cancer treatment, alongside established treatments such as surgery, radiation therapy, and chemotherapy.

In simple terms, T lymphocytes are collected from the patient and genetically engineered to express a CAR, or chimeric antigen receptor. This receptor enables the modified T cells - now called CAR-T cells - to recognize a specific target on tumor cells. After the CAR-T cells are infused back into the patient, they can expand in the body, identify cells carrying that target, and attack and eliminate them.

 Image source: Lekha Mikkilineni and James N. Kochenderfer. Blood. 2017;130(24):2594-2602.

2. How Is CAR-T Different from Chemotherapy?

CAR-T and chemotherapy are different treatment approaches, and each has its own potential benefits and limitations.

Chemotherapy is a well-established treatment with decades of clinical experience behind it. Its common side effects are relatively well characterized, and treatment is often delivered over multiple cycles, so the overall treatment course may be longer.

CAR-T is a newer form of cell therapy, and some patients can achieve complete remission after treatment. However, CAR-T is not necessary or suitable for every patient.

Some patients with blood cancers or other malignancies may also need additional treatment in sequence, such as hematopoietic stem cell transplantation or targeted therapy.

For this reason, CAR-T and chemotherapy should not be viewed as treatments that simply replace one another. They may be used at different points in the treatment journey, depending on the individual situation. The most appropriate approach should be determined by the medical team after considering factors such as pathological subtype, disease stage, molecular features, treatment history, and response to previous chemotherapy.

Expert Perspective

As treatment for hematologic malignancies continues to evolve, conventional chemotherapy and immunotherapies such as CAR-T are likely to be used more widely in combination or sequence, with the aim of helping more patients achieve longer survival and a better quality of life.